Sumgen Biotech's Innovative subcutaneous injectable antibody SG301 SC Has Commenced First-In-Human Study

date:2023-11-20      source:

Hangzhou, China - November 20, 2023 - Hangzhou Sumgen Biotech Co., Ltd (hereinafter referred to as "Sumgen Biotech") is delighted to announce the successful administration of the first dose in human of our subcutaneous injectable antibody candidate SG301SC.  This achievement marks a significant advancement in the comprehensive clinical evaluation of SG301SC, following the successful kick-off meeting on October 25th. This clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of SG301 SC injection in patients with systemic lupus erythematosus. The study was led by Professor Zhang Jing and Professor Weiguo Wan, principal investigators from Huashan Hospital affiliated with the Shanghai Medical College of Fudan University.

Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044